摘要
目的探讨生脉饮配合放疗治疗非小细胞肺癌(NSCLC)的临床效果。方法选取2017年12月—2019年12月于本院进行就诊的NSCLC患者100例,根据随机数字表法将其分为观察组(n=50)和对照组(n=50)。对照组患者采用放疗治疗,观察组在其基础上采用生脉饮进行治疗,治疗时间为3个月。采用流式细胞仪对治疗前后两组患者外周血CD3^+、CD3^+CD4^+、CD3^+CD8^+、自然杀伤细胞(NK)、NKT和调节性T细胞(Treg)等T细胞亚群的水平进行检测;采用酶联免疫吸附法(ELISA)对外周血γ-干扰素(IFN-γ)、α-肿瘤坏死因子(TNF-α)、白细胞介素-2(IL-2)水平进行检测;参考实体瘤疗效评价标准(RECIST)对两组患者临床疗效进行评价;观察两组患者治疗期间不良反应的发生情况,并比较。结果治疗3个月后,观察组患者外周血CD3^+、CD3^+CD4^+、CD3^+CD8^+、NK、NKT、Treg水平均显著高于对照组,差异均有统计学意义(P<0.05);治疗3个月后,观察组患者的外周血IFN-γ、TNF-α、IL-2水平显著高于对照组,差异均有统计学意义(P<0.05);观察组患者的临床总有效率(48.00%)显著高于对照组(38.00%),差异有统计学意义(P<0.05);治疗期间,观察组患者不良反应的发生率(48.00%)显著低于对照组(74.00%),差异有统计学意义(P<0.05)。结论生脉饮配合放疗治疗NSCLC能够显著提高其临床疗效和患者免疫水平,降低不良反应的发生率,有一定的临床参考价值。
Objective To explore the clinical effect of Shengmai Decoction combined with radiotherapy in the treatment of non-small cell lung cancer(NSCLC).Methods From December 2017 to December 2019,100 NSCLC patients were selected and divided into observation group(n=50)and control group(n=50).The patients in the control group were treated with radiotherapy,while those in the observation group were treated with Shengmai Decoction for three months.The peripheral blood levels of CD3^+,CD3^+CD4^+,CD3^+CD8^+,natural killer cells(NK)and NKT were measured by flow cytometry.The levels of IFN-γ,TNF-αand IL-2 in peripheral blood were detected by enzyme-linked immunosorbent assay(ELISA).The clinical efficacy of the two groups was evaluated by referring to the evaluation standard of solid tumor efficacy(RECIST).The therapeutic period of the two groups was observed.The occurrence of adverse reactions was compared.Results After 3 months of treatment,the levels of CD3^+,CD3^+CD4^+,CD3^+CD8^+,NK,NKT and Treg in the observation group were significantly higher than those in the control group(P<0.05).After 3 months of treatment,the levels of IFN-γ,TNF-αand IL-2 in the observation group were significantly higher than those in the control group(P<0.05).The total clinical effective rate of the observation group(48.00%)was significantly higher than that of the control group(38.00%)and the difference was statistically significant(P<0.05).During the treatment,the incidence of adverse reactions of the observation group(48.00%)was significantly lower than that of the control group(74.00%)and the difference was statistically significant(P<0.05).Conclusion Shengmai Decoction combined with radiotherapy can significantly improve the clinical efficacy and immune levels of NSCLC patients,and reduce the incidence of adverse reactions.It has a certain clinical reference value.
作者
张晕生
鲍艳红
高帆
尚华
刘志伟
ZHANG Yunsheng;BAO Yanhong;GAO Fan;SHANG Hua;LIU Zhiwei(Qinhuangdao Fourth Hospital,Qinhuangdao 066000,Hebei,China)
出处
《辽宁中医杂志》
CAS
2020年第7期109-112,共4页
Liaoning Journal of Traditional Chinese Medicine
关键词
生脉饮
放疗
非小细胞肺癌
临床效果
Shengmai Decoction
radiotherapy
non-small cell lung cancer
clinical effect
作者简介
张晕生(1977-),女,河北抚宁人,副主任医师,硕士,研究方向:放疗与中医药结合减轻毒性反应。
